Morepen Labs. Reports Strong Financial Performance in Q1 FY25, with Highest Sales and Cash Flow.

Morepen Laboratories, a smallcap pharmaceutical company, has recently declared its financial results for the quarter ended June 2024. The company has shown a very positive performance in this quarter, with a score of 20 out of 20, as compared to 19 in the previous quarter.

One of the major highlights of the financial results is the growth in Profit Before Tax (PBT) and Profit After Tax (PAT). PBT has grown by 47.4% to Rs 44.74 crore, while PAT has grown by 50.5% to Rs 36.17 crore, as compared to the average of the previous four quarters. This shows a very positive trend in the near term for the company.

Another positive aspect is the Inventory Turnover Ratio, which has been consistently growing in the last five half yearly periods. This indicates that the company has been able to sell its inventory at a faster pace, resulting in better cash flow.

Speaking of cash flow, Morepen Labs. has generated the highest Operating Cash Flow of Rs 77.36 crore in the last three years. This shows the company’s ability to generate higher cash revenues from its business operations.

In terms of sales, the company has achieved its highest quarterly sales of Rs 455.22 crore in the last five quarters, indicating a positive trend in the near term. The same can be seen in the Operating Profit (PBDIT) and Profit Before Tax (PBT) figures, which have also reached their highest in the last five quarters.

The company’s Earnings per Share (EPS) have also shown a positive trend, reaching its highest at Rs 0.71 in the last five quarters. This indicates an increase in profitability and higher earnings for shareholders.

However, one area of concern is the Debtors Turnover Ratio, which has slowed down in the last five half yearly periods. This means that the company’s pace of settling its debtors has decreased.

Overall, Morepen Laboratories has shown a very positive financial performance in the quarter ended June 2024. With a ‘Buy’ call from MarketsMOJO, the company seems to be on the right track for growth and success in the pharmaceutical industry.